Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: The DRAGON study

Journal of Gastroenterology

Volumn 49, Issue 1, 2014, Pages 138-147

  Hayashi, Norio ^a   Seto, Chiharu ^b   Kato, Mai ^b   Komada, Yuji ^b   Goto, Shoichiro ^b  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b Janssen Pharmaceutical KK   (Japan)

Author keywords

Chronic hepatitis C; Direct acting antiviral; Protease inhibitor; Sustained virologic response

Indexed keywords

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84895074600     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0875-1     Document Type: Article

References (30)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74-81.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(Suppl 3):S206-14.
4. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676-91.
5. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346-53.
6. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53:39-43.
7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-64.
8. Arase Y, Kumada H. Treatment strategy for chronic hepatitis C in Japan. Nihon Rinsho. 2011;69(Suppl 4):180-4.
9. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology. 2010;78(Suppl 1):78-86.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
12. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
13. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-17.
14. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-16.
15. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292-303.
16. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
17. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134-42.
18. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78-84.
19. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
20. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int. 2012;32(Suppl 1):32-8.
21. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-24.
22. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I et al. TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study. In: Abstract presented at the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, USA, 4-8 November, 2011.
23. Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, et al. Rapid viral response of once-daily TMC435 plus peginterferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther. 2011;16:1021-33.
24. Sekar V, Vis P, Lenz O, Meyvisch P, Peeters M, De Smedt G. Pharmacokinetic-pharmacodynamic (PK-PD) analyses of TMC435 in treatment-naive hepatitis C (HCV)-infected patients in the OPERA-1 study. Poster 1075 presented at the 45th Annual Meeting of the European Association for the Study of the Liver, 14-18 April, Vienna, Austria, 2010.
25. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW et al. TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial. Abstract A-455-0022-00482 presented at the Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18-22 April, 2012.
26. Verloes R, Shishido A (2009) Phase I safety and PK of TMC435 in healthy volunteers and safety, PK and short-term efficacy in chronic hepatitis C infected individuals. Abstract O-32 presented at the Japanese Hepatology Congress, Kobe, Japan, 4-5 June, 2009.
27. Reddy KR, Lin F, Zoulim F. Response-guided and -unguided treatment of chronic hepatitis C. Liver Int. 2012;32(Suppl 1):64-73.
28. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81:452-8.
29. Lenz O, Vijgen L, Lin T-I, Verbinnen T, Berke JM, Meyvisch P, Simmen K, Fanning G. Analysis of the NS3 region in HCV genotype 1-infected patients treated with 5-day monotherapy of TMC435 in a Phase 1 study. In: 16th International Symposium on Hepatitis C Virus and Related Viruses, 3-7 October, Nice, France 2009; Poster P-247.
30. Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Poster 278 presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, October 29-November 2, 2010.